Skip to search formSkip to main contentSkip to account menu

motesanib diphosphate

Known as: 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2) 
The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

AMG 706

Broader (1)

Imetelstat
NiacinamideReceptor Tyrosine Kinase Inhibitionmotesanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Motesanib diphosphate can induce partial remissions in patients with progressive advanced metastatic differentiated thyroid cancer unresponsive to surgery, external beam radiotherapy and 131 I
SUMMARY BACKGROUND Thyroid cancers are highly vascular, overexpressing vascular endothelial growth factor (VEGF), which is a… 
2008
2008
AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors
3570 Background: AMG 102 is a novel, fully human monoclonal antibody that selectively targets hepatocyte growth factor/scatter… 
2008
2008
Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors
3560 Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In… 
2008
2008
Platelets and the vascular wall.
To the Editor: Sherman et al. (July 3 issue)1 highlight the importance of selecting patients for alternative therapies, such as…